Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir plus /- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs

被引：0
|
作者：
Alric, Laurent [1 ]
Leroy, Vincent [2 ]
Cotte, Laurent [3 ]
Anne, Minello [4 ]
Remy, Andre Jean [5 ]
Rouanet, Isabelle [6 ]
Godart, Marion [1 ]
Hezode, Christophe [7 ]
Abravanel, Florence [8 ]
Ollivier-Hourmand, Isabelle [9 ]
机构：
[1] CHU Purpan, Internal Med Digest Dept, Toulouse, France
[2] CHU, Digest Dept, Grenoble, France
[3] Hop Lyon, Digest Dept, Lyon, France
[4] CHU, Digest Dept, Dijon, France
[5] Hop Perpignan, Digest Dept, Perpignan, France
[6] CHU, Digest Dept, Nimes, France
[7] CHU Henri Mondor, Digest Dept, Creteil, France
[8] CHU Purpan, Virol, Toulouse, France
[9] CHU, Digest Dept, Caen, France
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1544
引用
收藏
页码：824A / 825A
页数：2
相关论文
共 50 条
  • [11] Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
    Dietz, Julia
    Spengler, Ulrich
    Mullhaupt, Beat
    zur Wiesch, Julian Schulze
    Piecha, Felix
    Mauss, Stefan
    Seegers, Barbara
    Hinrichsen, Holger
    Antoni, Christoph
    Wietzke-Braun, Perdita
    Peiffer, Kai-Henrik
    Berger, Annemarie
    Matschenz, Katrin
    Buggisch, Peter
    Backhus, Johanna
    Zizer, Eugen
    Boettler, Tobias
    Neumann-Haefelin, Christoph
    Semela, David
    Stauber, Rudolf
    Berg, Thomas
    Berg, Christoph
    Zeuzem, Stefan
    Vermehren, Johannes
    Sarrazin, Christoph
    Balavoine, J.
    Giostra, E.
    Berning, M.
    Hampe, J.
    De Gottardi, A.
    Rauch, A.
    Semmo, N.
    Discher, T.
    Trauth, J.
    Fischer, J.
    Gress, M.
    Guenther, R.
    Heinzow, H.
    Schmidt, J.
    Herrmann, A.
    Stallmach, A.
    Hilgard, G.
    Deterding, K.
    Lange, C. M.
    Ciesek, S.
    Wedemeyer, H.
    Hoffmann, D.
    Klinker, H.
    Schulze, P.
    Kocheise, F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (01) : 195 - +
  • [12] Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C
    Hezode, Christophe
    Fourati, Slim
    Chevaliez, Stephane
    Scoazec, Giovanna
    Soulier, Alexandre
    Varaut, Anne
    Francois, Murielle
    Ruiz, Isaac
    Roudot-Thoraval, Francoise
    Mallat, Ariane
    Pawlotsky, Jean-Michel
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (11) : 1615 - 1618
  • [13] Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients
    Droc, Gabriela
    Istrate, Mircea
    Mercan-stanciu, Andriana
    Dodot, Mihai
    Isac, Teodora
    Toma, Letitia
    Zgura, Anca
    Trifan, Anca
    Serbanica, Andreea Nicoleta
    Iliescu, Laura
    Micu, Laurentiu
    IN VIVO, 2022, 36 (06): : 2918 - 2922
  • [14] Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
    Hassnine, Alshymaa A.
    Soliman, Wail
    Elsayed, Amr M.
    Higazi, Mahmoud M.
    Saied, Mery
    Abdelraheem, Ehab M.
    EGYPTIAN LIVER JOURNAL, 2022, 12 (01)
  • [15] Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
    Alshymaa A. Hassnine
    Wail Soliman
    Amr M. Elsayed
    Mahmoud M. Higazi
    Mery Saied
    Ehab M. Abdelraheem
    Egyptian Liver Journal, 12
  • [16] C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF GT1-INFECTED PATIENTS WITH 12 WEEKS OF ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN AFTER FAILURE OF SHORT-DURATION ALL-ORAL THERAPY
    Lawitz, E. J.
    Poordad, F.
    Gutierrez, J.
    Wells, J.
    Landaverde, C.
    Reiling, J.
    Li, J. J.
    Huang, H. -C.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S763 - S763
  • [17] EFFICACY OF 12 OR 18 WEEKS OF GRAZOPREVIR PLUS ELBASVIR WITH RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV GENOTYPE 3-INFECTED PATIENTS
    Gane, E.
    Nahass, R.
    Luketic, V.
    Hwang, P.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S621 - S621
  • [18] Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients
    Lorenzini, Kuntheavy Ing
    Girardin, Francois
    LIVER INTERNATIONAL, 2020, 40 (01) : 32 - 44
  • [19] Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed
    Pol, Stanislas
    Sulkowski, Mark S.
    Hassanein, Tarek
    Gane, Edward J.
    Liu, Lin
    Mo, Hongmei
    Doehle, Brian
    Kanwar, Bittoo
    Brainard, Diana
    Subramanian, G. Mani
    Symonds, William T.
    McHutchison, John G.
    Nahass, Ronald G.
    Bennett, Michael
    Jacobson, Ira M.
    HEPATOLOGY, 2015, 62 (01) : 129 - 134
  • [20] Successful Retreatment With Sofosbuvir-Containing Regimens for HCV Genotype 2 or 3 Infected Patients Who Failed Prior Sofosbuvir Plus Ribavirin Therapy
    Nyberg, Lisa M.
    Lalezari, Jacob
    Ni, Liyun
    Doehle, Brian
    Kanwar, Bittoo
    Brainard, Diana M.
    Subramanian, G. M.
    Symonds, William T.
    McHutchison, John G.
    Rodriguez-Torres, Maribel
    GASTROENTEROLOGY, 2014, 146 (05) : S905 - S905
12345